Merck Serono call-rate targets: pressure for “6 calls/contacts per day” and uncertified field briefings (AUTH/2756/5/15)

📅 2015 | 🖉 Dr Anzal Qurbain
📊

Key facts

CaseAUTH/2756/5/15
PartiesAnonymous employee v Merck Serono
IssueCall rates / contact-rate targets and certification of field briefings
Product referencedRebif (interferon beta-1a)
Complaint received7 May 2015
Case completed24 July 2015
Applicable Code year2015
Breach clauses15.2, 15.4, 15.9
SanctionsUndertaking received; Additional sanctions: Not stated
AppealNo appeal
Field force context8 neurology KAMs; ~50–60 MS specialists per territory; March 2015 had 22 working days (Panel calculation: 6 contacts/day ≈ 132 contacts/month)

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous employee complained that, after a neurology leadership change (Jan 2015), the neurology sales team was targeted to see six prescribing customers daily.
  • What began as a March 2015 “additional incentive” (30% KPI incentive linked to achieving 6 contacts/day) was alleged to have become an ongoing required activity standard, with weekly activity reporting and follow-up emails to individuals who missed the target.
  • Territories reportedly had ~50–60 MS consultants and nurse specialists each (8 KAMs total), raising concerns that the target would drive unnecessary contact and inconvenience to HCPs.
  • Emails from management (including 30 April and 2 May 2015) used inconsistent terminology (“calls” vs “contacts”), pushed for volume, and did not consistently remind staff of Code constraints.
  • At least two key emails used as field force briefings (20 March and 2 May) were not certified before distribution.
⚖️

Outcome

  • Breach found of Clauses 15.2, 15.4 and 15.9.
  • The Panel concluded the March “incentive” operated in reality as a requirement and that meeting it would, on the balance of probabilities, lead to Code breaches due to likely inconvenience and inadequate/unclear guidance.
  • The Panel found that representatives were not given comprehensive and consistent guidance on achieving 6 contacts/day while remaining compliant, including failure to clearly distinguish expected call rates vs contact rates.
  • The Panel ruled that briefing material had been sent to representatives prior to certification.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training